Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balamapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 13/20 | 0.73 |
| ▸ | IGF1R | P08069 | 9/20 | 0.81 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balamapimod SCHEMBL30104249 | 1.00 | IGF1R (0.81) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2974425 | 0.99 | IGF1R (0.80) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2963305 | 0.95 | IGF1R (0.87) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2968693 | 0.94 | IGF1R (0.78) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2962949 | 0.94 | IGF1R (0.87) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2976171 | 0.94 | IGF1R (0.71) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2975567 | 0.94 | MAP2K1 (0.75) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL14418379 | 0.91 | IGF1R (0.67) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2964257 | 0.91 | IGF1R (0.82) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2966483 | 0.91 | IGF1R (0.66) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | claimed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2005082891-A1 | -QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2005-08-25 | — | — | US | claimed |
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12595260-B2 | Stable heavy isotopes in amide functional groups and uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12466819-B2 | Tricyclic compounds with OMA1/OPA1 modulatory properties | 712 NORTH INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250281607-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12365675-B2 | Stable heavy isotopes in amide functional groups and uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-07-22 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025096952-A1 | SCAFFOLDS AND SCAFFOLD HOLDERS FOR TISSUE ENGINEERING | UNIVERSITY OF CONNECTICUT (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240190859-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2024-06-13 | — | — | US | disclosed |
| US-7767671-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2010-08-03 | — | — | US | disclosed |
| US-7666901-B2 | -[(Diethylamino)methylene]-7,11-dihydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,10-dioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; antitumor, -carcinogenic, proliferative agents; imroved antitumor activity; nontoxic; TOR (target of rapamycin) inhibitors | WYETH (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
| US-7449460-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | WYETH (US) | 2006-06-15 | — | — | US | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005082891-A1 | -QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | STK17A, STK17B, HSD17B7 | MAP2K1 934/4885IGF1R 490/4885MAPK3 124/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | MAP2K1 1921/4885IGF1R 64/4885MAPK3 3557/4885 |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | RAF1, KRAS, NRAS | MAP2K1 89/4885IGF1R 862/4885MAPK3 11/4885 |
| US-12365675-B2 | Stable heavy isotopes in amide functional groups and uses thereof | AADAC, SLC10A1, SLC3A2 | MAP2K1 4187/4885IGF1R 786/4885MAPK3 4266/4885 |
| US-12466819-B2 | Tricyclic compounds with OMA1/OPA1 modulatory properties | OPA1, OLA1, ACOX1 | MAP2K1 4774/4885IGF1R 3235/4885MAPK3 4260/4885 |
| US-12595260-B2 | Stable heavy isotopes in amide functional groups and uses thereof | SLC10A1, SLC9A1, SLC10A6 | MAP2K1 2769/4885IGF1R 659/4885MAPK3 4434/4885 |
| US-20240190859-A1 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | AADAC, SLC10A1, SLC3A2 | MAP2K1 4187/4885IGF1R 786/4885MAPK3 4266/4885 |
| US-20050187247-A1 | 3-Quinolinecarbonitrile protein kinase inhibitors | RAF1, KRAS, NRAS | MAP2K1 89/4885IGF1R 862/4885MAPK3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.